News Quantified

KALA – kala pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

KALA BIO, Inc. (NASDAQ: KALA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock.

KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Announces $12,500,000 Private Placement

5.8%

BEAT

-1.6%

MISS

3.8%

BEAT

-4.6%

MISS

Oppenheimer Holdings Inc.

Form 424B5 KALA BIO, Inc.

Form 10-Q KALA BIO, Inc. For: Jun 30

Form 8-K KALA BIO, Inc. For: Aug 06

Form EFFECT KALA BIO, Inc.

Form 424B3 KALA BIO, Inc.

Top News Gainers

1/3 Form 4 Kala Pharmaceuticals, For: Jan 02 Filed by: Brazzell Romulus K 26.4%

3/7 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock. 26.3%

8/8 Kala Pharmaceuticals Inc (NASDAQ: KALA) was given a new $9.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a "buy" rating on the stock. 24.0%

8/7 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock, down previously from $15.00. 17.2%

11/7 Form 10-Q Kala Pharmaceuticals, For: Sep 30 10.8%

4/17 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 8.0%

4/1 Form 4 Kala Pharmaceuticals, For: Mar 30 Filed by: Chen Hongming 7.7%

10/21 Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 6.8%

4/13 Form 4 Kala Pharmaceuticals, For: Apr 09 Filed by: Brazzell Romulus K 6.8%

6/3 Form 4 Kala Pharmaceuticals, For: May 30 Filed by: Rosen Howard B 6.2%

Top News Decliners

3/11 Form 8-K Kala Pharmaceuticals, For: Mar 10 -16.0%

8/6 Form 8-K Kala Pharmaceuticals, For: Aug 06 -15.9%

8/3 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.75 price target on the stock. -15.1%

12/17 Kala Pharmaceuticals Inc (NASDAQ: KALA) was downgraded by analysts at Bank of America Corp from a "buy" rating to a "neutral" rating. They now have a $6.00 price target on the stock, down previously from $9.00. -13.2%

3/12 Form 424B5 Kala Pharmaceuticals, -8.8%

4/30 Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call -8.7%

1/21 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock. -8.4%

4/28 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. -7.5%

3/10 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its price target raised by analysts at Wedbush from $51.00 to $52.00. They now have an "outperform" rating on the stock. -7.1%

5/9 Form 10-Q Kala Pharmaceuticals, For: Mar 31 -6.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day